No drug-drug interactions between selective prolyl‐tRNA synthetase inhibitor, bersiporocin, and pirfenidone or nintedanib in healthy participants

• Main Authors: Wonsuk Shin (Author), Min Young Park (Author), Jongwoo Kim (Author), Jihyeon Kim (Author), Jun Hee Nam (Author), Jongwon Choi (Author), A‐Young Yang (Author), Hyounggyoon Yoo (Author), Yil‐Seob Lee (Author), Anhye Kim (Author)
• Format: Book
• Published: Wiley, 2024-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Bersiporocin, a potent and selective prolyl‐tRNA synthetase inhibitor, is expected to show a synergistic effect with pirfenidone or nintedanib in patients with idiopathic pulmonary fibrosis. To validate the combination therapy of bersiporocin with pirfenidone or nintedanib, a randomized, op...